Clinical Trial Update: Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating thalidomide for decreasing collagen biosynthesis in progressive systemic sclerosis. The study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• Thalidomide (thalidomide)

Snippet

Sponsor: NYU Langone Health | Conditions: Scleroderma, Systemic | Phase 1 | Status: TERMINATED